Cargando…
Relationships among microbiota, gastric cancer, and immunotherapy
Currently, conventional neoadjuvant therapy or postoperative adjuvant therapy, such as chemotherapy and radiation therapy, can only bring limited survival benefits to gastric cancer (GC). Median survival after palliative chemotherapy is also low, at about 8–10 months. Immunotargeting is a new option...
Autores principales: | Li, Yuzhen, Huang, Xiaona, Tong, Desheng, Jiang, Chenyu, Zhu, Xiaodan, Wei, Zhipeng, Gong, Tingjie, Jin, Chunhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511979/ https://www.ncbi.nlm.nih.gov/pubmed/36171746 http://dx.doi.org/10.3389/fmicb.2022.987763 |
Ejemplares similares
-
OncoVee™-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study
por: Zhang, Baonan, et al.
Publicado: (2023) -
Individualized therapy based on the combination of mini-PDX and NGS for a patient with metastatic AFP-producing and HER-2 amplified gastric cancer
por: Zhu, Xiaodan, et al.
Publicado: (2022) -
Gut Microbiota and Immunotherapy
por: Xu, Xiaoqing, et al.
Publicado: (2022) -
Fungal Microbiota Dysbiosis and Ecological Alterations in Gastric Cancer
por: Yang, Ping, et al.
Publicado: (2022) -
Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice
por: Li, Yuzhen, et al.
Publicado: (2022)